RecruitingNCT06314919

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

A Multicenter, Prospective, Cohort Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimibe Under the Real-World Condition

Sponsor

Boryung Pharmaceutical Co., Ltd

Enrollment

8,606 participants

Start Date

Mar 15, 2024

Study Type

OBSERVATIONAL

Conditions

Primary hypercholesterolemia mixed dyslipidemia

Summary

The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition

Eligibility

Min Age: 19 Years

Inclusion Criteria2

Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia
Those who are judged to need administration of a fixed-dose combination of pitavastatin/ezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe

Exclusion Criteria3

Those who are taking a fixed-dose combination of pitavastatin/ezetimibe at study enrollment
Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe
Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.

Interested in this trial?

Get notified about updates and connect with the research team.